6 completed, 4 unknown, 2 active not recruiting, 2 terminated. 3 Not applicable, 3 Phase 4, 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 3 | Unknown 2, Active not recruiting 1 |
| Phase 4 | 3 | Completed 2, Withdrawn 1 |
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Terminated 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Adrenergic alpha-Antagonists: new trials by email Literature Review of Adrenergic alpha-Antagonists trials Research Report on Adrenergic alpha-Antagonists
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ultrasound IPP to Predict Response to Medical Therapy in LUTS/BPH Transabdominal ultrasound measurement of intravesical prostatic protrusion, Alpha-adrenergic blocker, 5-alpha reductase inhibitor - Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms | Completed | Ain Shams University | 130 | 2025-12-30 | 2026-09-30 | |
| Management and Outcome of Scorpion Sting in Children Alpha blocker - Scorpion Stings | Not yet recruiting | Assiut University | 70 | 2024-11-01 | 2024-09-26 | |
| A 6-months Observational Study to Evaluate the Quality of Life of Patients Treated With Phytotherapy or Alpha-blockers for Benign Prostatic Hyperplasia Phytotherapy - Benign Prostatic Hyperplasia | Completed | Pierre Fabre Medicament | 288 | 2022-06-22 | 2025-08-27 | |
| (Phosphodiesterase 5 Inhibitors & α-blockers): Single Versus Combined Therapy in Benign Prostatic Hyperplasia Phosphodiesterase 5 Inhibitors, Alpha Blockers, Combined Alpha Blockers and Phosphodiesterase 5 Inhibitors - Benign Prostatic Hyperplasia | Not applicable | Unknown | Assiut University | 120 | 2022-05-01 | 2022-02-11 |
| REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men REZŪM, alpha blocker and 5-alpha reductase inhibitor - Benign Prostatic Hyperplasia (BPH) | Not applicable | Active not recruiting | Boston Scientific Corporation | 155 | 2021-09-15 | 2026-10-13 |
| Intermittent Catheterization Versus Trial Without Catheter intermittent catheterization, trial without catheter, alpha-blockers - Benign Prostatic Hyperplasia | Not applicable | Unknown | Moscow State University of Medicine and Dentistry | 200 | 2021-08-03 | 2021-10-26 |
| Efficacy of α-blocker or 5-ARI Withdrawal to Continued Combination Therapy on the Maintenance of LUTS in Men With BPH alpha-blocker or 5-ARI withdrawal, Maintenance of alpha-blocker and 5-ARI - Prostatic Hyperplasia, Prostate Hyperplasia | Phase 3 | Unknown | Gangnam Severance Hospital | 300 | 2020-12-08 | 2021-08-27 |
| Impact of Mirabegron on Erectile Function in BPH Patients Mirabegron 50 MG, Alpha Blockers - Males With Benign Prostatic Hyperplasia Symptoms | Unknown | Kasr El Aini Hospital | 100 | 2020-10-01 | 2020-08-10 | |
| Prazosin to Prevent COVID-19 (PREVENT-COVID Trial) Prazosin, Standard of care - COVID-19 | Phase 2 | Terminated | Johns Hopkins University | 5 | 2020-05-13 | 2023-04-10 |
| Role of Sympathetic Vasoconstriction on Insulin-Mediated Microvascular Recruitment and Glucose Uptake in Obesity Phentolamine, Saline, Sodium Nitroprusside - Insulin Resistance, Healthy | Phase 1 | Active not recruiting | Vanderbilt University Medical Center | 36 | 2017-10-24 | 2026-03-02 |
| Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives all approved antihypertensive drugs; all approved statins - Stroke, Transient Ischemic Attack | Phase 4 | Completed | Istituto Auxologico Italiano | 200 | 2013-04-01 | 2024-02-20 |
| WEUSKOP5723: Prostate Cancer Study 5-alpha reductase inhibitors, Alpha-blockers - Prostatic Hyperplasia | Completed | GlaxoSmithKline | 1 | 2012-11-01 | 2016-11-09 | |
| A Study Comparing the Efficacy of an Alpha Blocker Versus an Alpha Blocker Plus Solifenacin in Men With Overactive Bladder Alpha blocker, placebo, solifenacin - Urinary Bladder, Overactive | Phase 4 | Completed | KYU-SUNG LEE | 94 | 2008-06-01 | 2016-01-07 |
| The Clinical Efficacy of Non-steroidal Anti-inflammation Drugs in Patients With Benign Prostatic Hyperplasia selective alpha 1-blockers, celecoxib, alpha-blocker and NSAID - Benign Prostatic Hyperplasia | Phase 4 | Withdrawn | Samsung Medical Center | 2008-05-01 | 2013-06-10 | |
| Observational Study in Patients Suffering From Benign Prostatic Hyperplasia Treated With Alpha-adrenergic Blockade alpha-adrenergic blocker - Prostatic Hyperplasia | Completed | Boehringer Ingelheim | 4561 | 2000-01-01 | 2014-09-19 | |
| Effect of Caldine® on Renal Function in Balanced Hypertension Lacidipine, Diuretics, antihypertensive drugs - Hypertension | Terminated | Boehringer Ingelheim | 5417 | 1998-05-01 | 2014-09-16 |
Prostatic Hyperplasia (9) · Hypertension (2) · Lower Urinary Tract Symptoms (2) · COVID-19 (1) · Cytokine Release Syndrome (1) · Dementia (1) · Heart Failure (1) · Insulin Resistance (1) · Ischemic Attack, Transient (1) · Myocardial Infarction (1) · Obesity (1) · Respiratory Distress Syndrome (1) · Scorpion Stings (1) · Stroke (1) · Urinary Bladder Neck Obstruction (1)
Assiut University (2) · Boehringer Ingelheim (2) · Ain Shams University (1) · Boston Scientific Corporation (1) · Gangnam Severance Hospital (1) · GlaxoSmithKline (1) · Istituto Auxologico Italiano (1) · Johns Hopkins University (1) · KYU-SUNG LEE (1) · Kasr El Aini Hospital (1) · Moscow State University of Medicine and Dentistry (1) · Pierre Fabre Medicament (1) · Samsung Medical Center (1) · Vanderbilt University Medical Center (1)
South Korea (3) · Egypt (2) · France (2) · Russia (2) · United States (2) · Australia (1) · Spain (1)
Alberto Zanchetti (1) · Chetan Bettegowda, MD/PhD (1) · Evanguelos Xylinas, Ass. Prof. (1) · Kyo Chul Koo, MD, PhD (1) · Kyu-Sung Lee, Ph.D., M.D. (1) · Lisheng Liu, MD (1) · Mohamed E Osman, MD (1) · Romain Mathieu, Professor (1) · Vigen Malkhasyan (1)
PMID 14499682, PMID 14660839, PMID 18542722, PMID 24384790, PMID 24979303, PMID 32905623, PMID 36398903